AIM ImmunoTech Inc
AIM1.155USD
-0.055-4.55%
시장 운영 시간 （ET）시세는 15분 지연됩니다
3.20M시가총액
손실P/E TTM
자세한 내용은 AIM ImmunoTech Inc 회사
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM ImmunoTech Inc 정보
종목 코드 AIM
회사 이름AIM ImmunoTech Inc
상장일Jul 12, 1996
CEOEquels (Thomas K)
직원 수21
유형Ordinary Share
회계 연도 종료Jul 12
주소2117 Sw Highway 484
도시OCALA
증권 거래소NASDAQ OMX – NASDAQ Basic Amex
국가United States of America
우편 번호32801
전화13524487797
웹사이트https://aimimmuno.com/
종목 코드 AIM
상장일Jul 12, 1996
CEOEquels (Thomas K)
AIM ImmunoTech Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.91K
-15.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-3.00%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-1.00%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
-1.00%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.91K
-15.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-3.00%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-1.00%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
-1.00%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sun, Nov 16
마지막 업데이트: Sun, Nov 16
주주
주주 유형
주주
주주
비율
DRW Securities, LLC
1.52%
Equels (Thomas K)
1.36%
Kellner (Theodore D)
1.31%
Sabby Management, LLC
1.01%
The Vanguard Group, Inc.
0.61%
기타
94.19%
주주
주주
비율
DRW Securities, LLC
1.52%
Equels (Thomas K)
1.36%
Kellner (Theodore D)
1.31%
Sabby Management, LLC
1.01%
The Vanguard Group, Inc.
0.61%
기타
94.19%
주주 유형
주주
비율
Individual Investor
3.86%
Investment Advisor
2.18%
Investment Advisor/Hedge Fund
1.58%
기타
92.38%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
56
107.25K
2.64%
--
2025Q3
59
107.25K
2.79%
+95.13K
2025Q2
58
12.12K
12.55%
-36.20K
2025Q1
67
48.31K
13.00%
-45.65K
2024Q4
64
46.48K
14.87%
-43.65K
2024Q3
61
90.13K
15.18%
+5.69K
2024Q2
61
84.44K
8.12%
+43.50K
2024Q1
64
40.95K
9.51%
-6.49K
2023Q4
65
41.55K
9.71%
-1.72K
2023Q3
69
43.37K
10.32%
-1.62K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
DRW Securities, LLC
43.29K
1.52%
+43.29K
--
Sep 30, 2025
Equels (Thomas K)
38.87K
1.36%
-15.00
-0.04%
Oct 24, 2025
Kellner (Theodore D)
37.20K
1.3%
+17.51K
+88.91%
Oct 24, 2025
Sabby Management, LLC
28.86K
1.01%
+28.86K
--
Sep 30, 2025
The Vanguard Group, Inc.
17.50K
0.61%
+17.50K
--
Sep 30, 2025
Deutsch (Todd A)
17.16K
0.6%
--
--
Dec 19, 2024
Geode Capital Management, L.L.C.
16.19K
0.57%
+16.19K
--
Sep 30, 2025
Mitchell (William M)
5.22K
0.18%
-4.00
-0.08%
Oct 24, 2025
Rodino (Peter W III)
4.01K
0.14%
-7.00
-0.17%
Oct 24, 2025
Appelrouth (Stewart L.)
3.89K
0.14%
+670.00
+20.82%
Dec 31, 2024
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Mar 03, 2025
Merger
100→1
날짜
배당락일
유형
비율
Mar 03, 2025
Merger
100→1
